You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Not yet recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • (no location specified)
2022-03-15
Mar 15, 2022
U
Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
2022-02-22
Feb 22, 2022
I
Completed
  • Splenic Marginal Zone Lymphoma
    • Bellinzona, Switzerland
      IOSI
    2021-06-04
    Jun 4, 2021
    B
    Recruiting
    • Relapsed/Refractory Marginal Zone Lymphoma
    • Westbury, New York
      Clinical Research Alliance, Inc.
    2022-03-29
    Mar 29, 2022
    I
    Not yet recruiting
    • Follicular Lymphoma ( FL)
    • Marginal Zone Lymphoma (MZL)
    • (no location specified)
    2022-02-07
    Feb 7, 2022
    U
    Recruiting
    • Follicular Lymphoma (Gastric or Duodenal)
    • Marginal Zone Lymphoma (Gastric or Duodenal)
    • Radiation Therapy
    • Münster, North Rhine-Westphalia, Germany
      Department of Radiation Oncology
    2021-12-01
    Dec 1, 2021
    B
    Recruiting
    • MZL
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    2021-07-28
    Jul 28, 2021
    U
    Recruiting
    • Chronic Lymphocytic Leukemia
    • +5 more
      • Strasbourg, France
        Hematology Laboratory - Strasbourg University Hospitals
      2021-07-02
      Jul 2, 2021
      H
      Recruiting
      • Marginal Zone Lymphoma
      • Zhengzhou, Henan, China
        Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
      2021-08-15
      Aug 15, 2021
      A
      Active, not recruiting
      • Lymphoma, Non-Hodgkin
      • +5 more
      • Providence, Rhode Island
        Rhode Island Hospital and The Miriam Hospital
      2021-07-19
      Jul 19, 2021
      N
      Suspended
      • Follicular Lymphoma
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      N
      Recruiting
      • Recurrent Follicular Lymphoma
      • +8 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      2021-12-16
      Dec 16, 2021
      B
      Not yet recruiting
      • Follicular Lymphoma
      • +2 more
      • New Haven, Connecticut
      • +2 more
      2022-03-14
      Mar 14, 2022
      B
      Recruiting
      • Follicular Lymphoma and Marginal Zone Lymphoma
      • Recombinant Humanized Monoclonal Antibody MIL62 Injection
      • Lenalidomide
      • Beijing, China
        Chinese Academy of Medical Sciences and Peking Union Medical Col
      2021-06-15
      Jun 15, 2021
      U
      Recruiting
      • Follicular Lymphoma
      • +2 more
      • Laboratory Biomarker Analysis
      • Pembrolizumab
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      2021-12-15
      Dec 15, 2021
      B
      Recruiting
      • Diffuse Large B-Cell Lymphoma
      • +14 more
      • La Jolla, California
      • +1 more
      2022-01-10
      Jan 10, 2022
      F
      Recruiting
      • Lymphoma, T-Cell, Cutaneous
      • +5 more
      • Registry of patients (exposure is Cutaneous Lymphoma)
      • Barcelona, Spain
      • +13 more
      2022-03-15
      Mar 15, 2022
      U
      Active, not recruiting
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • Miami, Florida
        University of Miami
      2021-10-25
      Oct 25, 2021
      M
      Completed
      • Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
      • +2 more
      • Radiation Therapy
      • Houston, Texas
        M D Anderson Cancer Center
      2022-02-25
      Feb 25, 2022
      B
      Recruiting
      • Follicular Lymphoma and Marginal Zone Lymphoma
      • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
      • lenalinomide
      • Beijing, China
        Chinese Academy of Medical Sciences and Peking Union Medical Col
      2022-02-13
      Feb 13, 2022
      K
      Active, not recruiting
      • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
      • +8 more
      • PI3K inhibitor BKM120
      • +3 more
      • Atlanta, Georgia
      • +1 more
      2021-09-29
      Sep 29, 2021
      I
      Active, not recruiting
      • Marginal Zone Lymphoma of Ocular Adnexal
      • Messina, Italy
      • +6 more
      2021-06-04
      Jun 4, 2021
      Y
      Suspended
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +23 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      2022-02-23
      Feb 23, 2022